 |
1 Disease |  |
0 Trials |
|
0 Trials |  |
6 News |  |
- ALN-AAT / Alnylam
Trial termination: A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease (clinicaltrials.gov) - Mar 19, 2018
P1/2, N=26, Terminated, Sponsor: Alnylam Pharmaceuticals
Active, not recruiting --> Terminated; Observation of low incidence of asymptomatic, transiently elevated liver enzymes in a subset of study subjects
- | ALN-AAT / Alnylam
Enrollment change, Trial primary completion date: A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease (clinicaltrials.gov) - Nov 27, 2017
P1/2, N=26, Active, not recruiting, Sponsor: Alnylam Pharmaceuticals
Active, not recruiting --> Terminated; Observation of low incidence of asymptomatic, transiently elevated liver enzymes in a subset of study subjects N=66 --> 26 | Trial primary completion date: Dec 2015 --> Feb 2018
- || ALN-AAT / Alnylam
Trial primary completion date: A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease (clinicaltrials.gov) - Jun 5, 2017
P1/2, N=66, Active, not recruiting, Sponsor: Alnylam Pharmaceuticals
N=66 --> 26 | Trial primary completion date: Dec 2015 --> Feb 2018 Trial primary completion date: Jan 2017 --> Dec 2015
- ||| ALN-AAT / Alnylam
Enrollment closed: A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease (clinicaltrials.gov) - May 16, 2016
P1/2, N=66, Active, not recruiting, Sponsor: Alnylam Pharmaceuticals
Trial primary completion date: Jan 2017 --> Dec 2015 Recruiting --> Active, not recruiting
- ||||| ALN-AAT / Alnylam
New P1/2 trial: A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease (clinicaltrials.gov) - Jul 21, 2015
P1/2, N=66, Recruiting, Sponsor: Alnylam Pharmaceuticals